Punicalagin Targets Atherosclerosis: Gene Expression Profiling of THP-1 Macrophages Treated with Punicalagin and Molecular Docking.
THP-1 macrophages
atherosclerosis
gene expression
molecular docking
punicalagin
Journal
Current issues in molecular biology
ISSN: 1467-3045
Titre abrégé: Curr Issues Mol Biol
Pays: Switzerland
ID NLM: 100931761
Informations de publication
Date de publication:
12 May 2022
12 May 2022
Historique:
received:
12
04
2022
revised:
03
05
2022
accepted:
04
05
2022
entrez:
9
6
2022
pubmed:
10
6
2022
medline:
10
6
2022
Statut:
epublish
Résumé
Atherosclerosis is an important cause of cardiovascular disorders worldwide. Natural botanical drugs have attracted attention due to their antioxidant, anti-inflammatory, and antiatherogenic properties in the treatment of atherosclerosis. Punicalagin is the major bioactive component of pomegranate peel, and has been shown to have antioxidant, anti-inflammatory, antiviral, anti proliferation, and anticancer properties. To explore its antiatherogenic properties at a molecular level, we investigated the genome-wide expression changes that occur in differentiated THP1 cells following treatment with a non-toxic dose of punicalagin. We also conducted a molecular docking simulation study to identify the molecular targets of punicalagin.
Identifiants
pubmed: 35678674
pii: cimb44050145
doi: 10.3390/cimb44050145
pmc: PMC9164052
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2153-2166Références
Biochim Biophys Acta Mol Basis Dis. 2019 Sep 1;1865(9):2538-2550
pubmed: 31202985
BMC Med. 2013 May 01;11:117
pubmed: 23635324
Nutrients. 2019 Nov 15;11(11):
pubmed: 31731808
J Agric Food Chem. 2000 Oct;48(10):4581-9
pubmed: 11052704
Nature. 2000 Sep 14;407(6801):233-41
pubmed: 11001066
Mol Pharm. 2018 May 7;15(5):1735-1745
pubmed: 29140707
Urol Oncol. 2013 Nov;31(8):1419-29
pubmed: 23141781
Atherosclerosis. 1999 Jul;145(1):33-43
pubmed: 10428293
Oxid Med Cell Longev. 2016;2016:7124251
pubmed: 27516832
Oxid Med Cell Longev. 2017;2017:8526438
pubmed: 29317985
Nutr Metab Cardiovasc Dis. 2014 Jun;24(6):639-47
pubmed: 24552647
J Nutr. 2006 Oct;136(10):2481-5
pubmed: 16988113
Pharmaceuticals (Basel). 2020 Nov 08;13(11):
pubmed: 33171640
Curr Pharmacol Rep. 2018 Feb;4(1):64-90
pubmed: 29527458
BMC Complement Altern Med. 2017 Jan 14;17(1):47
pubmed: 28088220
IBRO Rep. 2019 May 09;6:153-159
pubmed: 31193374
Curr Atheroscler Rep. 2013 May;15(5):324
pubmed: 23512608
Oxid Med Cell Longev. 2018 Jul 31;2018:2673076
pubmed: 30151068
Am J Clin Nutr. 2000 May;71(5):1062-76
pubmed: 10799367
Theranostics. 2020 Jan 1;10(1):17-35
pubmed: 31903103
Cell Cycle. 2006 Feb;5(4):371-3
pubmed: 16479165
Sci Signal. 2020 Mar 24;13(624):
pubmed: 32209697
Evid Based Complement Alternat Med. 2012;2012:382763
pubmed: 23243442
Biochem Biophys Res Commun. 2006 Dec 15;351(2):376-82
pubmed: 17067553
Int J Gynecol Cancer. 2016 Nov;26(9):1557-1563
pubmed: 27540692
Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4896-901
pubmed: 15781875
J Recept Signal Transduct Res. 2020 Apr;40(2):173-180
pubmed: 32024401
J Agric Food Chem. 2008 Feb 13;56(3):1148-57
pubmed: 18173244
Drugs Exp Clin Res. 2002;28(2-3):49-62
pubmed: 12224378
Cardiovasc Res. 2007 Jan 15;73(2):414-23
pubmed: 17014835
Nutrients. 2019 Mar 16;11(3):
pubmed: 30884808
Annu Rev Nutr. 2014;34:281-303
pubmed: 24850384
Biochim Biophys Acta. 2012 Oct;1822(10):1608-16
pubmed: 22705205